| IAP |
Cancer |
Mechanism of inhibition |
Increased sensitivity to |
Ref. |
| XIAP |
Colorectal |
shRNA |
TRAIL
Taxanes
γ-irradiation |
[100] |
| Breast |
shRNA |
TRAIL
Taxanes |
[101] |
| siRNA |
Etoposide
Doxorubicin |
[102] |
| Lapatinib |
[59] |
| Lung |
Antisense |
Doxorubicin
Taxol
Vinorelbine
Etoposide |
[103] |
| siRNA |
Cisplatin |
[68] |
| Pancreatic |
siRNA |
Doxorubicin
Paclitaxol |
[104] |
| Melanoma |
Dacarbazine
TRAIL |
[105] |
| Survivin |
Lung |
siRNA |
Adriamycin |
[106] |
| Cisplatin
Paclitaxol |
[107] |
| Breast |
siRNA |
Adriamycin |
[108] |
| Melanoma |
TRAIL |
[105] |
| Hepatocellular |
siRNA |
Radiotherapy |
[109] |
| Antisense |
TRAIL |
[110] |
| cIAP2 |
Pancreatic |
siRNA |
Doxorubicin
Paclitaxel |
[104] |
| Oral Squamous |
siRNA |
5-flurouracil |
[111] |
| Colorectal |
[112,113] |
| cIAPs |
Glioblastoma |
Smac mimetic |
Imatinib |
[114] |
| Smac mimetic (BV6) |
γ-irradiation |
[78] |
| Non small cell lung carcinoma |
Smac mimetic (JP1201) |
Doxorubicin
Erlotinib
Gemcitabine
Paclitaxol
Vinorelbine |
[115] |
| Smac mimetc (BV6) |
Radiotherapy |
[116] |
| Breast |
Smac mimetic (SM164) |
TRAIL |
[116] |
| Smac mimetic (Compound C) |
Herceptin |
[59] |
| Prostate |
Smac mimetic (SM164) |
TRAIL |
[117] |
| Colon |
|
